(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
@ $261.16
Utstedt: 3 mai 2024 @ 15:31
Avkastning: 0.47%
Forrige signal: mai 1 - 19:54
Forrige signal:
Avkastning: 3.96 %
Live Chart Being Loaded With Signals
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally...
Stats | |
---|---|
Dagens volum | 540 354 |
Gjennomsnittsvolum | 503 172 |
Markedsverdi | 11.64B |
EPS | $0 ( 2024-05-01 ) |
Neste inntjeningsdato | ( $5.65 ) 2024-06-25 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 13.25 |
ATR14 | $6.25 (2.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-05-02 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-05-02 | Rothblatt Martine A | Buy | 3 600 | Common Stock |
2024-05-02 | Rothblatt Martine A | Sell | 191 | Common Stock |
2024-05-01 | Rothblatt Martine A | Sell | 238 | Common Stock |
INSIDER POWER |
---|
-56.66 |
Last 100 transactions |
Buy: 31 200 | Sell: 112 800 |
Volum Korrelasjon
United Therapeutics Corp Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
BOCH | 0.917 |
EMBCV | 0.911 |
PUI | 0.882 |
ISRG | 0.874 |
SHSP | 0.864 |
MMAC | 0.852 |
HALO | 0.85 |
HOUR | 0.838 |
IBCP | 0.837 |
IMKTA | 0.837 |
10 Mest negative korrelasjoner | |
---|---|
GAINL | -0.934 |
APOP | -0.93 |
TDAC | -0.928 |
RMRM | -0.876 |
ISNS | -0.861 |
CMLF | -0.852 |
INZY | -0.826 |
NTEC | -0.819 |
MAGS | -0.814 |
SVOK | -0.813 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
United Therapeutics Corp Korrelasjon - Valuta/Råvare
United Therapeutics Corp Økonomi
Annual | 2023 |
Omsetning: | $2.33B |
Bruttogevinst: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2023 |
Omsetning: | $2.33B |
Bruttogevinst: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2022 |
Omsetning: | $1.94B |
Bruttogevinst: | $1.79B (92.42 %) |
EPS: | $15.98 |
FY | 2021 |
Omsetning: | $1.69B |
Bruttogevinst: | $1.56B (92.73 %) |
EPS: | $10.60 |
Financial Reports:
No articles found.
United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.